Posted by Michael Wonder on 05 Aug 2021
Eiger announces FDA breakthrough therapy designation for avexitide for treatment of congenital hyperinsulinism
5 August 2021 - All five orphan programs now have breakthrough therapy designation.
Eiger BioPharmaceuticals today announced that the U.S. FDA has granted breakthrough therapy designation for avexitide for the treatment of congenital hyperinsulism.
